Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Kite Pharma, Inc. (KITE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2017 |
8-K
| Quarterly results |
| 05/08/2017 |
8-K
| Form 8-K - Current report |
| 02/28/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 08/08/2016 |
8-K
| Form 8-K - Current report |
| 05/09/2016 |
8-K
| Quarterly results |
| 02/29/2016 |
8-K
| Quarterly results |
| 11/12/2015 |
8-K
| Quarterly results|
Docs:
|
"Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update Santa Monica, Calif., November 12, 2015 - Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015. “Over the past few months, we have achieved many significant corporate and clinical development milestones, including the initiation of two pivotal Phase 2 studies of our lead product candidate, KTE-C19,” noted Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer. “Our ZUMA-1 trial is enrolling patients with aggressive, refractory non-Hodgkin's lymphoma, while our ZUMA-2 trial is enrolling patients with relap..." |
|
| 08/10/2015 |
8-K
| Quarterly results|
Docs:
|
"Kite Pharma Reports Second Quarter 2015 Financial Results SANTA MONICA, Calif., August 10, 2015 — Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today reported financial results for the quarter ended June 30, 2015. “This past quarter has been marked by a number of significant milestones. Most notably, we launched the first Company-sponsored clinical trial of our lead product candidate, KTE-C19,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. “We also entered into multiple collaborations, and expanded our manufacturing capabilities. In addition, we were very pleased to convene our first investor day on June 23rd , which allowed us to unveil new..." |
|
| 05/15/2015 |
8-K
| Quarterly results|
Docs:
|
"Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 — Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today reported financial results for the quarter ended March 31, 2015. “We're very pleased with our accomplishments this year, which have significantly expanded our platform for discovering and advancing both chimeric antigen receptor and T cell receptor product candidates,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. “We've entered into a broadly enabling CAR collaboration with Amgen and acquired new TCR assets with the acquisition of TCF™ in the Netherlands. Further, we are excited to have secured ne..." |
|
| 03/26/2015 |
8-K
| Quarterly results|
Docs:
|
"Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results SANTA MONICA, Calif., March 26, 2015 — Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today reported full-year and fourth quarter 2014 financial results for the period ended December 31, 2014. “2014 was a transformative year for Kite, marked by achieving several key corporate and clinical milestones,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. “In addition to our successful IPO and follow-on offering, we expanded our management team with world-class talent, filed our first investigational new drug application for our lead product candidate KTE-C19, and entered into a m..." |
|
| 11/14/2014 |
8-K
| Quarterly results |
| 08/14/2014 |
8-K
| Quarterly results |
|
|